Challenges and opportunities in developing Actinium-225 radiopharmaceuticals

Area of Science:

• Nuclear Medicine
• Radiopharmaceutical Chemistry
• Oncology

Background:

• Actinium-225 (225Ac) is a promising therapeutic radioisotope for targeted alpha therapy due to its decay chain emitting four alpha particles.
• The limited availability and high cost of 225Ac, primarily produced from depleted thorium-229, hinder its widespread clinical use.

Purpose of the Study:

• To provide a comprehensive review of Actinium-225 (225Ac) radiopharmaceuticals.
• To discuss the challenges and opportunities in 225Ac production, labeling chemistry, in-vivo kinetics, and dosimetry.
• To summarize the current status of 225Ac radiopharmaceuticals in preclinical and clinical settings.

Main Methods:

• Review of existing literature on 225Ac production methods (cyclotrons, reactors, linear accelerators).
• Analysis of labeling chemistry strategies for 225Ac conjugates.
• Evaluation of in-vivo behavior, pharmacokinetics, and dosimetry studies.
• Compilation of data on 225Ac radiopharmaceuticals in preclinical and clinical development.

Main Results:

• Various production routes are being optimized to increase 225Ac availability.
• Advances in labeling chemistry enable the development of targeted 225Ac agents.
• Understanding in-vivo kinetics and dosimetry is crucial for effective and safe therapy.
• Several 225Ac radiopharmaceuticals are progressing through preclinical and clinical trials.

Conclusions:

• Actinium-225 (225Ac) holds significant potential for targeted alpha therapy, but production challenges remain.
• Continued research in production, chemistry, and clinical evaluation is essential to realize the full therapeutic benefit of 225Ac.
• Optimized 225Ac radiopharmaceuticals are expected to play a vital role in future cancer treatment strategies.